“We believe that paxalisib is rapidly becoming one of the most promising drug candidates in the global pipeline for this very challenging disease and we will be working strenuously to make it available to patients as quickly and efficiently as possible. “
IMO
This news Global pipeline - should easily allow the company to complete a CR at a huge premium to current share price
Rikki - imo time to get for real
Thats why they if accurate they are completing a CR at 40c market cap $30m for a global pipeline candidate
Newbies beware of the common theme around here not shown in share price or capital raisings
Ann: Kazia paxalisib Phase II interim data, page-16
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)